Leukaemia Trial, Recruiting NCT07246213 Sponsor: Resonance, Inc. Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT07246213
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their agreement to take part before enrolling in the registry (for children or those unable to give consent themselves, a parent or legal guardian must also give their agreement)
  • People who received a confirmed cancer diagnosis of any type within the 15 years before the trial site began operating
  • People who were aged between 0 and 21 years old at the time of their cancer diagnosis
  • People who received meaningful cancer treatment at the participating centre, such as chemotherapy, surgery, radiation therapy, or immunotherapy
  • People whose medical records are available and can be reviewed by the research team

Who may not be able to join:

  • People who only visited the participating centre for a consultation, without going on to receive their main cancer treatment there
  • People who only attended the participating centre for tests such as pathology or radiology, without receiving any cancer treatment there

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +1-901-205-9518

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Resonance, Inc.
Registry
ClinicalTrials.gov
Start date
4 June 2025
Est. completion
4 June 2028

Where this trial is recruiting

Armenia El Salvador Guatemala Honduras

Primary endpoints

To estimate the incidence of treatment failure, in patients with any type of cancer diagnosis.; To estimate the incidence of therapy related toxicities in patients diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov